secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001764013-22-000114
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023
--------------------------------------------------------------------------------

- Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.
- Phase 2 trial of batoclimab in Graves' Disease to start early 2023; initial results expected H2 2023.
- Batoclimab now in five indications: MG, TED, CIDP, Graves', and wAIHA (trial design pending regulator interaction later 2022).
- Data readouts expected every half-year from H2 2023 through H1 2025 across multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/0001764013-22-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/imvt-20220907.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer